The Ministry of industry and information technology and other nine departments recently issued the “14th five year plan” for the development of pharmaceutical industry (hereinafter referred to as the “plan”). The plan proposes that during the 14th Five Year Plan period, the development environment and development conditions of the pharmaceutical industry will face profound changes, and will enter a new stage of high-quality development of accelerating innovation driven development, promoting the modernization of the industrial chain and integrating into the global industrial system at a higher level.
According to the plan, the economies of scale of China Meheco Group Co.Ltd(600056) industry in the 14th five year plan will grow steadily. Innovative drugs and intelligent upgrading of the industrial chain are important growth points
the total profit of the pharmaceutical industry in the 14th five year plan has an average annual growth rate of more than 8%
Based on a comprehensive analysis of the scale benefit indicators of the pharmaceutical industry during the 13th Five Year Plan period and taking into account the technological development and policy changes at home and abroad, the plan proposes that the average annual growth rate of the operating revenue and total profit of the pharmaceutical industry during the 14th Five Year Plan period will remain above 8%, and the proportion of added value in all industries will increase to about 5%, The concentration of industry leading enterprises was further improved.
The plan also puts forward a 15 year long-term vision. By 2035, the strength of the pharmaceutical industry will achieve an overall leap; The pattern of innovation driven development has been fully formed, the industrial structure has been upgraded, there are more types of products and better quality, so as to achieve a higher level to meet the health needs of the people and provide a solid guarantee for building a healthy China in an all-round way
innovative drugs are the new driving force of the pharmaceutical industry
The 14th five year plan is a critical period for China Meheco Group Co.Ltd(600056) industrial innovation driven transformation. Therefore, the plan requires us to speed up product innovation and technological breakthroughs in industrialization. Facing the world’s scientific and technological frontier, the main battlefield of the economy, major national needs and people’s life and health, aiming at the international advanced technology level, continuously improve the innovation system, improve the industrial innovation ecology, vigorously promote the development and industrialization of innovative products, and promote the transformation of the development of the pharmaceutical industry to innovation driven.
“During the 13th Five Year Plan period, the added value of China’s pharmaceutical industry above designated size increased by an average of 9.5% a year. This growth rate is mainly driven by demand, and generic drugs and APIs account for a large proportion. In the next five years, the pharmaceutical industry will develop with high quality and the weight of innovative drugs will be significantly increased.”
Wang Xuegong, vice president of China Meheco Group Co.Ltd(600056) Enterprise Management Association, told reporters, “thanks to the accumulated strength in the past decade, China’s innovative drugs are in a state of thick accumulation and thin development.”
The report on building an China Meheco Group Co.Ltd(600056) innovation ecosystem (2021-2025) released by the China Meheco Group Co.Ltd(600056) innovation promotion association pointed out that in terms of the number of drug R & D, China’s contribution to the world jumped from about 4% in 2015 to about 14% in 2020, second only to the United States; In terms of the number of new drugs first listed in the world, China ranks among the top three in the world, accounting for 6%, which is significantly higher than 2.5% from 2007 to 2015.
Thanks to the efforts of major pharmaceutical enterprises, in 2021, the State Food and drug administration has approved 81 new drugs to be listed, which is a new high compared with 48 new drugs in 2020.
“The goal of a new high number of innovative drugs on the market in the 14th five year plan is certain to be achieved. In this process, leading pharmaceutical enterprises focusing on innovation will get good growth opportunities.” Wang Xuegong said
pay attention to the product differentiation characteristics of innovation leaders
According to the prediction of toubao Research Institute, from 2020 to 2025, China’s innovative drug industry will maintain a compound annual growth rate of 18.5% and continue to grow rapidly. By 2023, the market scale will reach 254.9 billion yuan.
However, it should also be noted that at present, the homogenization of innovative drug research and development in China is relatively serious, the targets and indications are relatively concentrated, and there are many uncertainties in the commercial rate of return. Troubled by these problems, innovative pharmaceutical enterprises performed poorly in the capital market last year.
Shanxi Securities Co.Ltd(002500) believes that the industry is gradually transforming and upgrading from me too / me worth to higher quality and more innovative me better and first in class. The advantages of China’s innovation leading enterprises with strong R & D strength, rich pipelines, reasonable gradient and outstanding product differentiation advantages will be further highlighted. It is suggested to pay attention to Jiangsu Hengrui Medicine Co.Ltd(600276) , Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) .
Shanxi Securities Co.Ltd(002500) it is also expected that with the promotion of policies and the continuous improvement of technical level, the industry concentration is expected to further improve. It is suggested to pay attention to industry leaders and subdivided leaders, such as Wuxi Apptec Co.Ltd(603259) , Porton Pharma Solutions Ltd(300363) .
Southwest Securities Co.Ltd(600369) believes that after the correction and shock in 2021, most of the innovative drug targets of A-Shares and Hong Kong stocks have good cost performance, so it is recommended to pay active attention to them. Related targets include Jiangsu Hengrui Medicine Co.Ltd(600276) , Shanghai Junshi Biosciences Co.Ltd(688180) , Betta Pharmaceuticals Co.Ltd(300558) , Corning Jerry pharmaceutical, Cinda biology, Suzhou Zelgen Biopharmaceuticals Co.Ltd(688266) , Frontier Biotechnologies Inc(688221) , etc
make systematic requirements for industrial chain upgrading for the first time
China Meheco Group Co.Ltd(600056) industry needs innovation. Innovation here not only refers to increasing R & D investment and innovating pharmaceutical technology, but also reflected in digital, integrated and intelligent research and application.
One of the five key tasks to be implemented by the “14th five year plan” China Meheco Group Co.Ltd(600056) industry is to “promote the upgrading of pharmaceutical manufacturing capacity system”. The plan calls for accelerating the construction of manufacturing power and quality power, deeply implementing intelligent manufacturing, green manufacturing and quality improvement actions, improving the quality management level and product quality of drugs and medical devices in the whole life cycle, promoting the high-end, intelligent and green development of the pharmaceutical industry, and promoting the development of the Internet, big data, blockchain Artificial intelligence and other new generation information technologies are integrated with the manufacturing system to improve the quality, efficiency and core competitiveness of the whole industry.
“The 14th five year plan has devoted a lot of space to put forward systematic requirements for the China Meheco Group Co.Ltd(600056) manufacturing industrial chain, which shows that the government attaches great importance to the upgrading of the whole industrial chain.” Guo Wen said
several listed companies have laid out intelligent
Affected by the epidemic situation and the implementation of policies such as “purchasing with quantity” and “two ticket system” of drugs in recent years, the income and profits of China Meheco Group Co.Ltd(600056) manufacturing enterprises have been greatly impacted. In this context, pharmaceutical enterprises have the ability, willingness and appeal to upgrade intelligent manufacturing.
Some listed companies have tried. For example, Tiansheng pharmaceutical’s “new mode application project of digital workshop for oral solid preparations of traditional Chinese medicine” has a well-established national advanced intelligent intelligent manufacturing workshop for solid preparations of traditional Chinese medicine, which realizes the high integration of advanced equipment, information management software and enterprise business processes.
For the pretreatment of traditional Chinese medicine in longfengtang under Yangzi pharmaceutical, the production line is equipped with a dust removal system to achieve zero dust emission and zero environmental pollution; The automation system of the workshop can be seamlessly connected with the logistics system, realizing the whole process automation from the delivery of raw medicinal materials, the washing, moistening, cutting and drying production line to the storage of net medicinal materials; The whole production, whole process online monitoring, whole process data acquisition and video monitoring.
In the Jiuzhitang Co.Ltd(000989) intelligent factory of solid preparations of traditional Chinese medicine, the application of intelligent equipment has significantly changed the company’s previous pharmaceutical experience, greatly improved work efficiency and more stable product quality.
Some listed companies are about to upgrade. Zhejiang Jolly Pharmaceutical Co.Ltd(300181) announced on January 26 that it plans to raise 910 million yuan for the construction and upgrading of intelligent traditional Chinese medicine production base.
Wang Xuegong believes that “in the next five years, pharmaceutical enterprises with advanced manufacturing technology, green and low-carbon production links and product quality meeting international standards will be able to develop well.”
